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Introduction: Depressive symptoms are a frequent and distressing phenomenon in
Multiple Sclerosis (MS) patients. Cross-sectional research links these symptoms to
reduced brain gray matter volumes in parts of the prefrontal and temporal lobe as well
as subcortical structures like the hippocampus, nucleus caudatus and globus pallidus.
Nevertheless, prospective relationships between regional gray matter volume and the
course of depressive symptoms are poorly understood.
Methods: Forty-four patients with relapsing–remitting or secondary progressive MS
participated in a prospective study with two assessments of depressive symptoms
and high-resolution MRI with an inter-test-interval of 17 months. Relationships between
baseline gray matter volume and baseline depressive symptoms, as well as prospective
associations between the development of atrophy and depression were assessed using
voxel-based morphometry (VBM).
Results: Cross-sectional analyses revealed an association between depressive
symptoms and gray matter loss in the left temporal lobe. Prospective analysis showed
that gray matter losses in the right middle cingulate and middle frontal gyrus at baseline
predicted increasing depressive symptoms during follow-up. Increase in depressive
symptoms was related to a concomitant increase in atrophy in the left thalamus and
right globus pallidus.
Discussion: Our results fit well into the concept of a disturbed
cortico–striatal–pallido–thalamic loop in depression. In this framework, progressive
gray matter loss in limbic basal ganglia structures including globus pallidus and
thalamus may lead to depression-typical deficits in hedonic motivation, whereas
atrophy of the prefrontal cortex may contribute to maladaptive coping strategies,
promoting an unfavorable development of depressive symptoms.
Keywords: multiple sclerosis, depression, structural MRI, prediction, prospective study
INTRODUCTION
Depression is a frequent accompanying symptom of Multiple Sclerosis (MS) with a lifetime
prevalence of 50% in patients, a replicated figure derived from tertiary care neurological
clinics. This prevalence is three times higher than in the general population (Feinstein, 2007).
Depression is one of the most important determinants of low quality of life in MS patients
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and seems to predict cognitive decline during the next years
(Christodoulou et al., 2009). Accordingly, the relationship
between structural brain changes and depressive symptoms
in MS has been the focus of extensive empirical research.
Here, brain atrophy or demyelination in the frontal lobe, the
temporal lobe and the hippocampus has been related to increased
depressive symptoms in MS patients (Gold et al., 2010; Kiy et al.,
2011; Feinstein et al., 2014; Gobbi et al., 2014; Patejdl et al.,
2016).
Both, depressive mood and structural brain abnormalities,
are more common in MS patients compared to healthy subjects
and thus it seems plausible that there is a MS-specific signature
of depression-related brain structure changes. It is however
a matter of ongoing debate whether the relationship between
brain structure changes and depressive symptoms is comparable
between samples with and without MS. To some degree, the
results from research focusing on depressive patients without
a somatic disease indeed mirror those from MS patients with
depression. In these studies, reduced gray matter volumes in
depressed patients without MS compared to healthy controls has
been reported particularly for the frontal and anterior cingulate
cortex (van Tol et al., 2010; Peng et al., 2011), the hippocampus
(Campbell et al., 2004; Zou et al., 2010; Cole et al., 2011), the
nucleus caudatus (Kim et al., 2008) and the globus pallidus
(Lacerda et al., 2003; Bielau et al., 2005). For the amygdala,
mixed results of decreased and increased sizes in depressed
compared to healthy subjects has been reported, potentially
due to varying treatment conditions of the investigated groups
(Hamilton et al., 2008). A meta-analysis on 20 studies comparing
regional brain volume of depressive patients with healthy control
subjects found gray matter reductions in depressive patients in
the bilateral anterior cingulate cortex, right middle and inferior
frontal gyrus, right hippocampus and left thalamus (Du et al.,
2012).
It is important to note, that all of these studies used a
cross-sectional design, i.e., they have related brain atrophy to
depression severity at one point in time. Thus, they could not
elucidate associations between brain structure at one (baseline)
time-point and future course of depressive symptoms or a
concomitant development of depression and atrophy in time.
The only prospective finding with respect to relationships
between brain atrophy and depression is a small size of the
hippocampus that has consistently been related to a poorer
prospective clinical performance in depressive patients without
MS (Frodl et al., 2008; Fu et al., 2013). Moreover, to the best
of our knowledge, no study has hitherto directly related the
course of depressive symptoms to the concomitant development
of brain atrophy in the relevant brain regions (which requires
MRI assessments at baseline as well as follow-up). With respect
to this gap, the present study aims at:
1. Replicating previous findings on cross-sectional relationships
between depression and brain atrophy patterns.
2. Informing whether experiencing depression at visit 1 might
promote the development of a specific pattern of regional
brain atrophy (for example in the hippocampi and therefore
explain the depression-related loss of memory performance
observed in two longitudinal studies (Christodoulou et al.,
2009; Hildebrandt and Eling, 2014)).
3. Informing whether a specific pattern of brain atrophy at visit 1
is related to an increased risk for the patients to develop
depressive mood in future.
4. Correlating the increase of brain atrophy over a period of time
with the increase of depressive mood and therefore allowing
for a more causal interpretation of the relation between
dysfunctions of the brain and the experience of depression,
which is not possible using cross-sectional studies.
Using a prospective study design with two assessments of
depressive symptoms and structural MRI in MS patients with
an interval of 17 months, we were able to test these associations
between regional brain volume and depressive symptoms, as well
as the change of brain volume and depressive symptoms between
the two visits.
MATERIALS AND METHODS
Subjects and Study Design
The initial sample comprised 46 MS patients that participated
in an ongoing prospective, non-interventional study on MRI
parameters characterizing progression of MS. The inclusion
criteria were age of 18–65 years, diagnosis of relapsing–remitting
(RRMS) or secondary progressive MS according to the
McDonald criteria 2001 but no relapse during the last 4 weeks
before the investigation, and an Expanded Disability Status Scale
(EDSS) of 0–6.5. The ethical board of the Bremer Physicians
Society approved the study and all patients gave informed
consent. The study involved two visits with a mean interval of
17 months in between (the original study design laid down an
interval of 18 months but due to the fast response of the patients
at follow-up, we obtained a mean of 17 months). A different
(fatigue-related) analysis of the same data set has already been
published (Sander et al., 2016): we also refer to this article for
further study details.
Of the initially 46 MS patients, two had to be excluded due to
missingMRI or depression assessments at visit 1. Four additional
subjects dropped out during follow-up, so that the final sample
comprised 44 patients for cross-sectional analyses at visit 1 and
40 patients for prospective analyses.
Assessment of Depressive Symptoms and
MS-Related Clinical Status
Depressive symptoms were quantified at visit 1 and visit 2 using
the Beck Depression Inventory (BDI; Beck et al., 1961). The
course of depressive symptoms between the two visits was
calculated by subtracting the BDI score at visit 1 from the
BDI score at visit 2 (thus with negative values indicating an
improvement and positive values indicating a worsening of
depressive symptoms). The change in EDSS scores was calculated
accordingly.
To detect possible differences between patients with RRMS
and SPMS, we compared the two subtypes with regard to BDI
scores at t1 and t2 as well as change in BDI scores between the
two visits. To exclude the possibility, that changes in depression
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severity and its relationships with brain atrophy might be
confounded by MS progress (e.g., due to the administration
of corticosteroids that also affect brain volume), we computed
correlations between change in BDI scores and change in
EDSS scores as well as with the number of relapses during
follow-up.
MRI Image Acquisition and Preprocessing
High-resolution T1 MPRAGE MRI images were acquired
at visit 1 and 2 using a 3T scanner (Siemens Skyra,
Erlangen, Germany) at an isotropic resolution of
1 mm3 × 1 mm3 × 1 mm3. These images were normalized into
MNI space and segmented into gray and white matter using the
preprocessing procedure for longitudinal data as implemented
in the voxel-based morphometry toolbox version 8 (VBM8) for
statistical parametric mapping version 8 (SPM8). This approach
uses the DARTEL (Ashburner, 2007) normalization algorithm
and the standard SPM tissue probability map. Subsequently,
maps showing gray matter volume change from visit 1 to visit
2 were created by voxel-wise subtracting the normalized images
at visit 1 from the images at visit 2, yielding a measure of
increase in atrophy between the two visits. Finally, the gray
matter volume maps for visit 1 as well as the gray matter volume
change maps (difference in gray matter from visit 1 to visit 2)
were smoothed with a 6 mm3 × 6 mm3 × 6 mm3 full-width
at half-maximum isotropic Gaussian kernel and used for the
following analyses.
Additional to the VBM analyses, the lesion load of
corticospinal tract was determined based on FLAIR-weighted
MRI images and using the technique outlined in (Klein et al.
(2015); Fraunhofer MEVIS NeuroQLab3.531 software package).
Changes in the lesion load were assessed by subtracting the lesion
load at visit 1 from the lesion load at visit 2.
Associations Between Gray Matter Volume
and Depressive Symptoms
Associations between gray matter volume and depressive
symptomswere assessed in four different ways. In all of these four
analyses, the magnitude of depressive symptoms (BDI score) or
its change between the two visits was voxel-wise correlated with
the gray matter volume or its change between the two visits using
the ‘‘Multiple Regression’’-design implemented in SPM8.
First, the cross-sectional relationship between gray matter
volume and severity of depressive symptoms was calculated with
a correlation analysis between the subjects’ BDI score at visit 1
and the gray matter volume at visit 1.
Second, the relationship between baseline depressive
symptoms and prospective development of gray matter volume
was calculated with a correlation analysis between subjects’ BDI
score at visit 1 and the change in gray matter volume from visit 1
to visit 2 (using the gray matter volume change maps). This
calculation tests, if stronger depressive symptoms at visit 1 are
associated with future gray matter volume losses in certain brain
regions (e.g., due to inflammatory processes).
Third, the relationship between baseline gray matter volume
and prospective development of depressive symptoms was
calculated with a correlation analysis between subjects’ gray
matter volume at visit 1 and the change in BDI scores
from visit 1 to visit 2. This calculation tests, if gray
matter volume reductions in a certain area at visit 1 are
associated with a worsening of depressive symptoms from
visit 1 to visit 2.
Fourth, the relationship between gray matter volume changes
and prospective development of depressive symptoms was
calculated with a correlation analysis between subjects’ change
in gray matter volume from visit 1 to visit 2 (using the gray
matter volume change maps) and change in BDI scores from
visit 1 to visit 2. This analysis tests, if the development of gray
matter volume in a certain area from visit 1 to visit 2 is related
to the development of depressive symptoms from visit 1 to
visit 2.
Associations Between Lesion Load and
Depressive Symptoms
Associations between lesion load of the corticospinal tract and
depressive symptoms were assessed in the same way as described
above for the VBM analyses. Accordingly, we computed
correlations between lesion load at visit 1 and BDI scores at visit 1
(cross-sectional relationships), between BDI scores at visit 1
and change in lesion load from visit 1 to visit 2 (prediction
of lesion development by depressive symptoms), between lesion
load at visit 1 and change in BDI scores (prediction of depression
development by baseline lesion load) and between changes in
lesion load from visit 1 to visit 2 and changes in BDI scores
from visit 1 to visit 2 (‘‘parallel’’ development of lesion load and
depressive symptoms).
Control Over Potential Confounders and
Significance Threshold
Since structural brain volumina are strongly age-dependent, we
included age as an additional covariate of no interest for every
analysis. Because the development of depressive symptomsmight
furthermore be dependent on the baseline severity of depressive
symptoms, the last two analyses testing the relationship between
gray matter volume and prospective development of depressive
symptoms were calculated with both, age and BDI scores at
visit 1, as covariates. To this end, these variables were included
as covariates in the multiple regression design of SPM8.
Because assessments of depression in MS patients may
be confounded by depression-like somatic symptoms such as
MS-related fatigue, we repeated all analyses using the affective
symptoms subscale of the BDI (Steer et al., 1999) instead of the
BDI total score. This validation analysis was aimed at minimizing
the impact of somatic depressive symptoms on the statistical
results. However, in none of the significant areas, results differed
substantially between the analyses with the BDI total score and
BDI affective symptoms subscale, so that for reasons of simplicity
only the results based on the BDI total score are reported in the
following.
All analyses were whole-brain analyses without a priori
regions of interest. Similar to previous VBM studies on
depression (Egger et al., 2008; Li et al., 2010; Peng et al., 2011;
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Liu et al., 2014), the results were considered significant at a
significance level of p < 0.001 uncorrected with an additional
cluster extent threshold of 50 contiguous voxels. Labeling of
the significant clusters was carried out using the established
advanced anatomic labeling atlas (AAL) and SPM8.
RESULTS
Patients: Age, Depressive Symptoms,
Medication and EDSS
Initially, 15 male and 29 female MS patients with a mean
age of 47.6 years, mean EDSS score of 3.7 and mean BDI
score of 10.4 were included. RRMS and secondary-progressive
multiple sclerosis (SPMS) patients did not differ significantly in
BDI scores at visit 1 (two-sample t-Test T = 1.35; p = 0.89),
visit 2 (two-sample t-Test T = 1.24; p = 0.22) or change in
BDI scores from visit 1 to visit 2 (two-sample t-Test T = 1.16;
p = 0.25).
In the 40 patients with reassessment at visit 2 (four drop-
outs), EDSS scores did not change significantly between visit 1
and visit 2, whereas BDI scores decreased by 2.9 points on
average (paired t-Test T = 3.25; p = 0.02). BDI and EDSS
scores showed a significant cross-sectional correlation at visit 1
(r = 0.32, p = 0.04), indicating worse depressive symptoms
with growing disability. The change in BDI scores however
was not associated with EDSS scores at visit 1 (r < 0.01,
p = 0.99) or the change in EDSS scores from visit 1 to visit 2
(r = 0.04, p = 0.82). Moreover, there was no association between
the number of relapses and the change in BDI scores from
visit 1 to visit 2 (Kendall-Tau rank correlation Tau = −0.30,
p = 0.82).
The characteristics and medications of the cross-sectional
sample (n = 44, used for the first analysis) and the longitudinal
sample (n = 40 due to the four drop-outs, used for the
three prospective analyses) are summarized separately in
Table 1.
Association Between Baseline Gray Matter
Volume and Baseline Severity of
Depressive Symptoms
First, we tested if reduced gray matter volume at visit 1 was
associated with the magnitude of depressive symptoms at visit 1.
This analysis revealed two significant clusters in the left temporal
lobe (Figure 1; first cluster MNI peak voxel [x, y, z] −44, 16,
−28; T-value peak voxel 5.58; cluster extent 508 voxels, AAL
labels middle and superior left temporal pole, second cluster
MNI = −58, −10, 4; T = 4.04; extent = 56; AAL = left superior
temporal gyrus).
Association Between Baseline Depressive
Symptoms and Subsequent Development
of Gray Matter Volume
Second, we tested if depressive symptoms at visit 1 were
associated with gray matter volume losses from visit 1 to visit 2.
This analysis revealed no significant results.
Association Between Baseline Gray Matter
Volume and Subsequent Development of
Depressive Symptoms
Third, we tested if reduced gray matter volume at visit 1 was
associated with the worsening of depressive symptoms from visit
1 to visit 2. This analysis revealed significant results for the
right cingulate cortex (Figure 2A; MNI = 12, 14, 46; T = 5.18;
extent = 66; AAL = right middle cingulate cortex) and the right
frontal lobe (Figure 2B; MNI = 32, 50, 16; T = 3.69; extent = 140;
AAL = right middle frontal gyrus).
TABLE 1 | Characteristics of patients included in the cross-sectional and longitudinal analyses.
Cross-sectional sample Longitudinal sample (visit 1) Longitudinal sample (visit 2)
Absolute numbers Absolute numbers Absolute numbers
n 44 40 40
Sex (male/female) 15/29 15/25 15/25
Antidepressant subscription (yes/no) 5/39 5/35 5/35
Form of MS (RR-MS/SP-MS) 33/11 29/11 29/11
Basic medication Interferon-beta (10), Interferon-beta (7), Interferon-beta (7),
glatiramer acetate (7), glatiramer acetate (7), glatiramer acetate (5),
natalizumab (7), natalizumab (7), natalizumab (5),
fingolimod (1), fingolimod (1), dimethyl fumarate (5),
teriflunomid (1), teriflunomid (1), fingolimod (1),
azathioprine (1), none (17) azathioprine (1), none (16) teriflunomid (1), none (16)
Relapses between visit 1 and visit 2 – – None (27), one (8), two (5)
Median (Interquartile Range) Median (Interquartile Range) Median (Interquartile Range)
Age (in years) 49 (16) 49 (18) 50.5 (18)
BDI 8.5 (10) 8 (9) 6 (7)
EDSS 3.75 (2.88) 3.75 (2.88) 3.5 (3)
BDI, Beck Depression Inventory; EDSS, Expanded Disability Status Scale; RR-MS, Relapsing-remitting multiple sclerosis; SP-MS, secondary-progressive multiple
sclerosis.
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FIGURE 1 | Areas showing a cross-sectional relationship between atrophy and magnitude of depressive symptoms at visit 1 (p < 0.001 uncorrected
and more than 50 contiguous voxels in a cluster). (A) Left temporal pole, MNI coordinates of peak voxel −44, 16, 28 (B) left superior temporal gyrus,
MNI coordinates of peak voxel −58, −10, 4.
Association Between Gray Matter Volume
Changes and Development of Depressive
Symptoms
Fourth, we assessed the relationship between increase in atrophy
and worsening of depressive symptoms over time. This analysis
revealed significant clusters in the left mediodorsal nucleus of the
thalamus (Figure 3A; MNI −5, −8, 6; T = 5.16; extent = 175;
AAL = left thalamus) and the right internal pallidum (Figure 3B;
MNI 14, −2, −2, T = 4.35; extent = 90; AAL = right globus
pallidus).
Associations Between Lesion Load and
Depressive Symptoms
Similar to our analyses of VBM data, we tested cross-sectional
and prospective relationships between the lesion load of
the corticospinal tract and depressive symptoms. Here, no
FIGURE 2 | Areas showing a relationship between atrophy at visit 1 and worsening of depressive symptoms from visit 1 to visit 2
(p < 0.001 uncorrected and more than 50 contiguous voxels in cluster). (A) Right middle cingulate cortex, MNI coordinates of peak voxel 12, 14, 46 (B) right
middle frontal gyrus, MNI coordinates of peak voxel 32, 50, 16.
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FIGURE 3 | Areas showing a relationship between increase in atrophy from visit 1 to visit 2 and worsening of depressive symptoms from visit 1 to
visit 2 (p < 0.001 uncorrected and more than 50 contiguous voxels in a cluster). (A) Left thalamus, MNI coordinates of peak voxel −5, −8, 6 (B) right globus
pallidus, MNI coordinates of peak voxel 14, −2, −2.
significant cross-sectional or longitudinal dependencies were
found.
DISCUSSION
In this prospective study, we tested cross-sectional and
prospective associations between brain gray matter volume
and depressive symptoms in a sample of MS patients. The
specific design of our study, including MRI scans at visit 1
and visit 2, allowed for the first time a combined analysis of
distinct temporal aspects of the relation between depression
and brain atrophy: we could distinguish ‘‘dynamical’’ aspects,
e.g., a concomitant development of depression and brain
atrophy, from ‘‘predictive’’ aspects (how the future course of
depression is predicted by certain patterns of atrophy) and
‘‘static’’ aspects (e.g., cross-sectional relationships at one point in
time).
We found a remarkable association between growing atrophy
in the left thalamus and the right internal globus pallidus
and worsening of depressive symptoms over time. Reduced
gray matter volumes of the right middle cingulate cortex and
middle frontal gyrus predicted a future worsening of depressive
symptoms. Furthermore, we could replicate previously reported
cross-sectional (static) relationships between regional brain
atrophy in the left temporal lobe and stronger depressive
symptoms.
The results fit well into the concept of a disturbed
cortico–striatal–pallido–thalamic loop in depression (Price and
Drevets, 2012). Based on studies on depression-related brain
atrophy, this concept has also been employed on depression
in the context of neurological diseases, particularly MS:
‘‘What may therefore link depression in a disparate set
of neurologic disorders is a disruption in neural circuits
originating in the prefrontal cortex and then sequentially
relaying in the striatum, globus pallidus, and thalamus, before
looping back to its prefrontal site of origin’’ (Feinstein
et al., 2004). Consistently, the two areas whose growing
atrophy was associated with growing severity of depressive
symptoms, (dynamic relationship in our study), i.e., the internal
globus pallidus and the mediodorsal thalamus, are closely
connected and part of a limbic/motivational basal ganglia
circuit (Nieuwenhuys et al., 2007). Central to our results,
it has been reported, that lesions in the globus pallidus
potentially lead to anhedonia and depression (Vataja et al.,
2001; Miller et al., 2006; Vijayaraghavan et al., 2008; Adam
et al., 2013), whereas deep brain stimulation of the pallidum
can alleviate these depressive symptoms (Kosel et al., 2007
for a case report, Vidailhet et al., 2005, for non-significant
trend in 22 patients). Both findings are consistent with a
suggested involvement of the globus pallidus in a dopaminergic
reward circuit (Hong and Hikosaka, 2008) that in turn
constitutes a convenient framework for the understanding
of the reported relationship between progressive atrophy
of this region and the course of depressive symptoms. In
such a framework, the reward-representing capacities of the
globus pallidus might diminish by its progressive atrophy,
thereby possibly promoting apathy and anhedonia as central
depressive symptoms. A potentially clinical relevant notion
is that this anhedonia associated with pallidum lesions can
partly be reversed by dopaminergic modulation (Adam et al.,
2013).
A reduced gray matter volume in the right prefrontal
cortex predicted a future worsening (or missing improvement)
of depressive symptoms. This finding is consistent with
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previous work by Gobbi et al. (2014), who also documented
atrophy in the right dorsolateral and inferior frontal
cortex in MS patients with depressive mood using VBM.
A (speculative) explanation for the relationship between
prefrontal atrophy and depression proneness might be
explained by a diminished capacity to adapt to and cope
with (disease-related) restrictions in subjects with more
pronounced prefrontal atrophy. This also ties with the finding
that depression in MS-patients is associated with impaired
executive functions (Feinstein, 2006) that are in turn dependent
on the integrity of the prefrontal cortex (Morgen et al.,
2006).
In our study, we found a cross-sectional (static) correlation
between magnitude of depressive symptoms and left anterior
temporal lobe atrophy. The previous cross-sectional research
yielded similar results on atrophy in the temporal pole,
but sometimes also in the frontal lobe and partly in the
right and not the left hemisphere (Feinstein et al., 2014). A
recent study using cortical thickness measures documented
atrophy in depressed MS patients both in the temporal and
the frontal cortex bilaterally (Nygaard et al., 2015). Hence,
it seems reasonable to argue that the anterior temporal
lobe and, probably, frontal areas play a role in MS-related
depression, but results are yet too inconsistent to argue for
a functional difference between both brain hemispheres in
this regard.
Our study was carried out on a sample of MS patients, in
which both depression and gray matter loss occur more frequent
than in the general population. Nevertheless, the patterns of
depression-related atrophy in our study closely resemble that
reported for depressive patients without somatic disease (Du
et al., 2012, for a meta-analysis), thereby suggesting similar
relationships between gray matter changes and depressive mood
in subjects with and without underlying MS.
Interestingly, average depressive symptoms did not worsen
over time but rather improved in our sample of MS patients.
This finding is in line with a recent longitudinal study on
the development of depression in MS, reporting stable or
improving depressive symptoms in the long term (Koch et al.,
2015).
The primary clinical measure of our study were changes in
subclinical depression, which is very common in MS patients
and thus a highly interesting and yet under investigated topic.
However, one should bear in mind that we did not investigate
cases of ‘‘full’’, clinically diagnosed depression, but related
symptom scores to gray matter densities in a correlational
approach. Thus, the validity of the results for clinical cases is
uncertain.
Taken together, our results suggest increasing damage
of subcortical motivational systems as a risk factor for
the development of depression in MS patients as well as
(intact) prefrontal function as a potential resilience factor.
Prospective studies are needed aiming at predicting the
development of depressive symptoms on basis of impaired
prefrontal functions and at preventing worsening of depressive
mood. Here, an application of dopaminergic antidepressants
like for example bupropion might be a promising approach
considering the depression-related atrophy in dopaminergic
motivational systems, whereas behavioral therapy focusing
on executive deficits might help to counteract prefrontal
impairments.
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